Although the clinical effectiveness of inhibitors of Bmi-1 for the treatment of head and neck cancers has not been extensively studied in published research, these small-molecule medications have shown promise in treating other malignancies in clinical and preclinical models, indicating that they may have novel applications in medicine. Here, BMI1 is linked to head and neck cancer.